New drug combo aimed at helping smokers with schizophrenia
NCT ID NCT06374290
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early pilot study tested whether a combination of injectable naltrexone and oral bupropion could help people with schizophrenia who smoke cigarettes. Only 2 participants were enrolled before the study was terminated. The main goals were to see if the treatment was feasible and safe, and to measure changes in smoking habits and schizophrenia symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
naltrexone (injectable) and bupropion (oral)
What this could lead to
If it works, this could point toward a new treatment option to help people with schizophrenia quit smoking.
What could go wrong
This was a very small pilot study (only 2 participants) that was terminated early, so results are limited. It is too early to know if the combination is effective or safe for this group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Texas health Science Center at Houston
Houston, Texas, 77030, United States